Comparative Burden of HbA1c and RBG Levels Among Individuals Above 25 Years in the Post-COVID-19 and Pre-COVID-19 Periods: A Retrospective Analysis at a Medical College Hospital, Ramanagara, Karnataka
Impact of COVID on RBG levels
Keywords:
Hyperglycemia, HBAIc, RBG, COVID, KarnatakaAbstract
Introduction
The COVID-19 pandemic significantly impacted public health, including metabolic health and glycemic control. SARS-CoV-2 affects glucose metabolism through inflammation, stress, and healthcare disruptions. HbA1c, a key diabetes marker, has shown increased levels post-COVID, suggesting higher hyperglycemia burden. In India, pre-COVID data revealed 12% of women and 14% of men over 15 years had RBG >140 mg/dl, with higher rates reported during COVID due to stress, inflammation, and treatment changes like corticosteroid use. We hypothesized a 15% rise in elevated HbA1c and RBG levels post-COVID among patients over 25 years. This study compared pre- and post-COVID trends by age and gender.
Methods:
The study was conducted at CDSIMER Hospital, as a retrospective observational analysis of HbA1c and RBG levels in patients aged >25 years. Two periods were compared: Pre-COVID-19 (2019–2021) and Post-COVID-19 (2022–2023). Data from the Laboratory Information System (LIS) and NFHS-5 reports were analyzed. Inclusion criteria included complete HbA1c and RBG records. The estimated sample size, based on previous studies, was 10,475.
Results:
A total of 17,238 patients data were analysed. In the post-COVID period, 16.95% had very high levels (?160 mg%), more than doubling from NFHS-5 data. Males showed a higher prevalence (22.15%) than females (12.86%). HbA1c >6.5% was found in 64% of individuals aged >25 years.
Conclusion:
Alarming increase in blood glucose levels among population aged above 25 years. National Health Programmes to take justifiable action on priority.
Downloads
Published
How to Cite
License
Copyright (c) 2025 shilpashree MK, Akshitha S, Leelambika

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
